{"generic":"Azathioprine Sodium","drugs":["Azathioprine Sodium","Imuran"],"mono":{"0":{"id":"923278-s-0","title":"Generic Names","mono":"Azathioprine Sodium"},"1":{"id":"923278-s-1","title":"Dosing and Indications","sub":[{"id":"923278-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Renal transplant rejection, Adjunct; Prophylaxis:<\/b> (initial) 3 to 5 mg\/kg IV as a single daily dose starting at the time of transplant; less commonly, therapy is started 1 to 3 days prior to transplantation; IV therapy (as sodium salt) is typically administered initially, and then patients are switched to oral therapy (at the same dosage) after the postoperative period<\/li><li><b>Renal transplant rejection, Adjunct; Prophylaxis:<\/b> (maintenance) 1 to 3 mg\/kg\/day<\/li><li><b>Rheumatoid arthritis:<\/b> (initial) 1 mg\/kg\/day (50 to 100 mg) IV as single dose or divided twice daily; may titrate by 0.5 mg\/kg\/day after 6 to 8 wk and every 4 wk thereafter; MAX dose is 2.5 mg\/kg\/day<\/li><li><b>Rheumatoid arthritis:<\/b> (maintenance) may lower dose by 0.5 mg\/kg\/day every 4 wk (while keeping other drug therapy constant) until lowest effective dose is reached<\/li><\/ul>"},{"id":"923278-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"923278-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>hematologic toxicity:<\/b> decrease the dosage or withhold therapy in patients who experience a rapid fall in or persistently low leucocyte counts or other signs of bone marrow depression; consider discontinuing therapy if CBC abnormalities persist despite dosage reduction<\/li><li><b>reduced thiopurine S-methyltransferase (TPMT) activity:<\/b> dosage reduction recommended<\/li><li><b>renal impairment:<\/b> usually administered at lower doses<\/li><\/ul>"},{"id":"923278-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Renal transplant rejection, Adjunct; Prophylaxis<\/li><li>Rheumatoid arthritis<\/li><\/ul>"}]},"2":{"id":"923278-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Powder for Solution)<\/b><br\/>Chronic immunosuppression with azathioprine, a purine antimetabolite, increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. Physicians should inform patients of the risk of malignancy with azathioprine.<br\/>"},"3":{"id":"923278-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923278-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to azathioprine<\/li><li>pregnant women with rheumatoid arthritis<\/li><li>rheumatoid arthritis patients who have received alkylating agents, including cyclophosphamide, chlorambucil, and melphalan; increased risk of malignancy<\/li><\/ul>"},{"id":"923278-s-3-10","title":"Precautions","mono":"<ul><li>malignancies, including lymphoma and skin cancer; increased risk, especially in renal transplant and rheumatoid arthritis patients<\/li><li>hepatosplenic T-cell lymphoma, including fatalities, has occurred, mostly in adolescent and young adult males being treated for Crohn's Disease or ulcerative colitis<\/li><li>rheumatoid arthritis; acute myelogenous leukemia and solid tumors have been reported<\/li><li>gastrointestinal hypersensitivity reaction, characterized by severe nausea and vomiting and possibly diarrhea, rash, fever, malaise, myalgias, liver enzyme elevations, and hypotension, has been reported, usually during first several weeks of therapy<\/li><li>hematological toxicity, severe, including leukopenia, thrombocytopenia, macrocytic anemia, and pancytopenia, may occur; monitoring recommended; reduction of dose or interruption may be necessary<\/li><li>infections, serious and opportunistic (eg, bacterial, viral, fungal, protozoal infections, JC virus-associated progressive multifocal leukoencephalopathy (PML), activation of latent viral infections); increased risk associated with immunosuppression<\/li><li>renal impairment; delayed clearance of drug or metabolites may occur; dosage adjustment may be necessary<\/li><li>renal transplant patients experiencing rejection; increased risk of hematologic toxicity; monitoring recommended; discontinuation may be necessary<\/li><li>thiopurine S-methyl transferase (TPMT) deficiency; increased risk of severe myelotoxicity; baseline TPMT genotype or phenotype testing recommended; alternate therapy or dose reduction recommended for patients with reduced TMPT activity<\/li><li>women of childbearing age; known teratogen; avoid pregnancy<\/li><\/ul>"},{"id":"923278-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Azathioprine: D (FDA)<\/li><li>Azathioprine: D (AUS)<\/li><\/ul>"},{"id":"923278-s-3-12","title":"Breast Feeding","mono":"<ul><li>Azathioprine: WHO: Avoid breastfeeding.<\/li><li>Azathioprine: Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"923278-s-4","title":"Drug Interactions","sub":[{"id":"923278-s-4-13","title":"Contraindicated","mono":"<ul>Febuxostat (theoretical)<\/ul>"},{"id":"923278-s-4-14","title":"Major","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (established)<\/li><li>Adenovirus Vaccine Type 7, Live (established)<\/li><li>Alacepril (theoretical)<\/li><li>Alfalfa (probable)<\/li><li>Allopurinol (established)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (established)<\/li><li>Benazepril (theoretical)<\/li><li>Black Cohosh (probable)<\/li><li>Captopril (established)<\/li><li>Cilazapril (theoretical)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Enalaprilat (probable)<\/li><li>Enalapril Maleate (probable)<\/li><li>Fosinopril (theoretical)<\/li><li>Influenza Virus Vaccine, Live (established)<\/li><li>Lisinopril (theoretical)<\/li><li>Measles Virus Vaccine, Live (established)<\/li><li>Mercaptopurine (theoretical)<\/li><li>Moexipril (theoretical)<\/li><li>Mumps Virus Vaccine, Live (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Olsalazine (probable)<\/li><li>Oxypurinol (established)<\/li><li>Pentopril (theoretical)<\/li><li>Perindopril (theoretical)<\/li><li>Poliovirus Vaccine, Live (established)<\/li><li>Quinapril (theoretical)<\/li><li>Ramipril (theoretical)<\/li><li>Ribavirin (probable)<\/li><li>Rotavirus Vaccine, Live (established)<\/li><li>Rubella Virus Vaccine, Live (established)<\/li><li>Smallpox Vaccine (established)<\/li><li>Spirapril (theoretical)<\/li><li>Sulfamethoxazole (theoretical)<\/li><li>Sulfasalazine (theoretical)<\/li><li>Trandolapril (theoretical)<\/li><li>Trimethoprim (theoretical)<\/li><li>Typhoid Vaccine (established)<\/li><li>Varicella Virus Vaccine (established)<\/li><li>Yellow Fever Vaccine (established)<\/li><li>Zofenopril (theoretical)<\/li><\/ul>"},{"id":"923278-s-4-15","title":"Moderate","mono":"<ul><li>Acenocoumarol (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Phenprocoumon (probable)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},"5":{"id":"923278-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Nausea and vomiting (12%)<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Pericarditis<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis, Hypersensitivity<\/li><li><b>Hematologic:<\/b>Acute myeloid leukemia, Anemia, Hematologic toxicity, Leukopenia (renal transplant, more than 50%; rheumatoid arthritis, 28%), Leukopenia (Severe), Less than 2500 cells\/mm[3] (renal transplant, 16%; rheumatoid arthritis, 5.3%), Macrocytic anemia, Megaloblastic anemia, Myelosuppression, Pancytopenia, Thrombocytopenia<\/li><li><b>Hepatic:<\/b>Hepatotoxicity (less than 1%), Lymphoma involves liver, Veno-occlusive disease of the liver<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction, Malignant lymphoma (0.5%), T-cell lymphoma, hepatosplenic<\/li><li><b>Neurologic:<\/b>Progressive multifocal leukoencephalopathy<\/li><li><b>Respiratory:<\/b>Adenocarcinoma of lung<\/li><li><b>Other:<\/b>Infectious disease (renal transplant, 20%; rheumatoid arthritis, less than 1%), Neoplastic disease (0.5% to 2.8%)<\/li><\/ul>"},"6":{"id":"923278-s-6","title":"Drug Name Info","sub":{"0":{"id":"923278-s-6-17","title":"US Trade Names","mono":"Imuran<br\/>"},"2":{"id":"923278-s-6-19","title":"Class","mono":"<ul><li>Antimetabolite<\/li><li>Antirheumatic, Cytotoxic<\/li><\/ul>"},"3":{"id":"923278-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"923278-s-7","title":"Mechanism Of Action","mono":"Azathioprine is an imidazolyl derivative of 6-mercaptopurine and acts as an immunosuppressive antimetabolite. The exact mechanism of immunosuppressive action is unknown because the exact mechanism of the immune response itself is complex and not completely understood. Azathioprine suppresses cell-mediated hypersensitivities and causes alterations in antibody production.<br\/>"},"8":{"id":"923278-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"923278-s-8-24","title":"Distribution","mono":"Protein binding: 30% <br\/>"},"2":{"id":"923278-s-8-25","title":"Metabolism","mono":"<ul><li>Azathioprine (prodrug), Liver: extensive oxidation or methylation<\/li><li>Azathioprine (prodrug), Erythrocytes: oxidation or methylation<\/li><li>6-Mercaptopurine: active<\/li><li>6-Thioguanine nucleotides (6-TGNs): active<\/li><\/ul>"},"3":{"id":"923278-s-8-26","title":"Excretion","mono":"<ul><li>Renal clearance: 57.3 mL\/min\/kg (prodrug IV administration)<\/li><li>Dialyzable: Yes, 45% over 8 hr<\/li><\/ul>"},"4":{"id":"923278-s-8-27","title":"Elimination Half Life","mono":"5 hr (35-S-azathioprine-containing metabolites) <br\/>"}}},"9":{"id":"923278-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>use proper procedures for handling and disposal of immunosuppressant agents<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>for IV use only<\/li><li>reconstitute vial with 10 mL Sterile Water for Injection (final vial dose of 100 mg); use within 24 hr<\/li><li>may further dilute in sterile saline or dextrose; volume depends on infusion duration<\/li><li>usual infusion time is 30 to 60 min (range, 5 min to 8 hr)<\/li><\/ul><\/li><\/ul>"},"12":{"id":"923278-s-12","title":"Toxicology","sub":[{"id":"923278-s-12-31","title":"Clinical Effects","mono":"<b>AZATHIOPRINE\/MERCAPTOPURINE <\/b><br\/>OVERDOSE: Nausea, vomiting, diarrhea, delayed leukopenia, increased SGOT and bilirubin, and impaired renal function can occur in overdose. ADVERSE EFFECTS: Fever, hepatitis, pancreatitis, skin rashes, and alopecia have developed Myelosuppression is the dose-limiting toxicity.<br\/>"},{"id":"923278-s-12-32","title":"Treatment","mono":"<b>AZATHIOPRINE\/MERCAPTOPURINE <\/b><br\/><ul><li>Decontamination: Activated charcoal<\/li><li>Support: Care is symptomatic and supportive.<\/li><li>Neutropenia: Severe neutropenia: filgrastim 5 mcg\/kg\/day subcutaneously, or sargramostim 250 mcg\/m(2)\/day infused over 4 hrs.<\/li><li>Enhanced elimination procedure: Azathioprine and metabolites are hemodialyzable<\/li><li>Monitoring of patient: Serial CBC with differential due to possible delayed neutropenia, hepatic enzymes and renal function<\/li><\/ul>"},{"id":"923278-s-12-33","title":"Range of Toxicity","mono":"<b>AZATHIOPRINE\/MERCAPTOPURINE<\/b><br\/>TOXIC DOSE: Not established. Transient neutropenia reported after azathioprine 7500 mg in an adult and 1 g (86 mg\/kg) in a toddler. No toxicity developed in an adult after 850 mg azathioprine. A toddler remained asymptomatic after up to 400 mg (26 mg\/kg) of 6-mercaptopurine. THERAPEUTIC: Azathioprine: 1 to 5 mg\/kg\/day orally. 6-mercaptopurine: 2.5 to 5 mg\/kg\/day orally.<br\/>"}]},"13":{"id":"923278-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient of increased risk of malignancies and to report persistent fevers, night sweats, or significant weight loss.<\/li><li>This drug may cause myelosuppression and gastrointestinal toxicity.<\/li><li>Instruct patient to report any unusual bleeding or bruising.<\/li><li>Instruct patient to report signs\/symptoms of infection.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}}}